Abstract Library

#4495 Clinicopathologic characteristics and prognostic analysis of rectal neuroendocrine tumours: A multicentre clinical study

Introduction: The incidence of rectal neuroendocrine tumours (R-NETs) has increased significantly in recent years.

Conference:

Presenting Author: Lian J

Authors: Lian J, Xing W, Lu H,

Keywords: Rectal Neuroendocrine Tumour, clinical data, real-world, CgA, progression-free survival,

#4409 The value of NETest 2.0 in stratifying patients with suspected NEN for formal diagnostic evaluation – Real-world data

Introduction: An unmet need in NEN diagnosis is better risk stratification for individuals with suspected disease (based on symptoms or imaging), enabling efficient identification of those needing further evaluation and tissue diagnosis, thus speeding the process and reducing costs. NETest 2.0, a biomarker based on a 51-gene mRNA panel, was developed for diagnosing neuroendocrine neoplasia (NEN).

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, at-risk population, NEN,

#4386 Streptozotocin- and temozolomide-based chemotherapy treatment in neuroendocrine neoplasms – Efficacy in patients treated outside clinical trials

Introduction: Chemotherapy treatment based on alkylating agents is useful in pancreatic and grade 3 neuroendocrine neoplasms (NENs). However, no current real-life data is available comparing streptozotocin (STZ) and temozolomide (TEM) combinations.

Conference:

Presenting Author: García-Álvarez A

Authors: García Alvarez A, Martínez-Badal S, García-Burillo A, Simó Perdigo M, Merino Casabiel X,

Keywords: Streptozotocin, temozolomide, neuroendocrine neoplasm,

#4309 Head-to-head comparison of 18F-AIF-NOTA-octreotide and 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine neoplasms

Introduction: 18F-AIF-NOTA-octreotide (F-Oc) is a radiolabelled SSA emerging as a potential alternative to 68Ga-DOTATATE (Ga-DT) due to logistical advantages. Recent studies indicate that F-Oc has comparable diagnostic accuracy to Ga-DT in neuroendocrine neoplasm (NEN) and, in some cases, can identify a greater number of lesions.

Conference:

Presenting Author: Bel-Ange A

Authors: Ben-Haim S, Bel-Ange A, Chicheportichee A, Maimon O, Aburbeh G,

Keywords: 68Ga-DOTATATE, NEN, 18F-AIF-NOTA-octreotide,

#4128 Validation of a 3-gene signature of response to axitinib in patients with advanced NETs

Introduction: Axitinib in combination with SSA significantly improved ORR and PFS per central blinded radiological assessment, as compared to placebo and SSA in 253 EP-NETs in the AXINET trial. The magnitude of the benefit, however, was limited. We recently described a 3-gene tumor transcriptomic signature predictive of response to axitinib in NET patients.

Conference:

Presenting Author: Lens-Pardo A

Authors: Lens-Pardo A, Carretero-Puche C, Antón-Pascual B, Capdevila J, Benavent M,

Keywords: axitinib, sunitinib, tyrosine kinase inhibitor, predictive biomarker, signature, elisa,